Clinical Trial Details


Research Study Summary

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery


This research is being done because even with the most aggressive after-surgery treatment with chemotherapy, many people still have the lung cancer recur (come back).

The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer. We will compare the effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on you and your lung cancer to see which is better at preventing the cancer from coming back.

Disease Characteristics:

  • Diagnosis of stage IB-IIIA (T2-3 N0, T1-3 N1, T1-3 N2) non-small cell lung cancer (NSCLC)
  • Patients with stage IB disease must have tumors measuring > 4 cm
  • Must have undergone complete resection of NSCLC within the past 6-12 weeks
  • Accepted types of resection include any of the following:
    • Lobectomy
    • Sleeve lobectomy
    • Bilobectomy
    • Pneumonectomy
  • No resection by segmentectomy or wedge resection
To Learn more

CW ID: 122109
Date Last Changed: July 25, 2013

Clinical Trial Snapshot

Both Male and Female
Overall Status
Facility Type


Cheryl Parish, RN, Manager, Oncology Clinical Trials
The Valley Hospital/Valley Health System
The Daniel and Gloria Cancer Center
One Valley Health Plaza
Paramus, NJ 07652
Phone: 201-634-5792

View Map

Research Center Information:

The Valley Hospital/Valley Health System

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.